文献速递认知障碍与痴呆

老年人APOE ε2ε4基因型与 incident AD、MCI、认知下降及AD病理

APOE ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults.
PubMed 文献 · Neurology · 2018-05-11

研究纳入2,151名基线无痴呆的欧洲血统老年人,按APOE基因型分组,分析ε2ε4与 incident AD、MCI、认知下降及尸检AD病理的关联。ε2ε4携带者与ε3ε3相比,基线无认知损害者 incident MCI风险升高、认知下降更快,尸检AD病理和β-淀粉样蛋白负荷更高,但AD风险无差异。

要点

  • ε2ε4与ε3ε3相比, incident AD风险无差异。
  • 基线无认知损害者中,ε2ε4携带者 incident MCI风险升高(HR 2.13,95%CI 1.34-3.39,p=0.002)。
  • ε2ε4携带者认知下降更快,尸检AD病理和β-淀粉样蛋白负荷更高。

核心结论

  • 老年人APOE ε2ε4基因型与MCI风险、认知下降及更重的AD病理(尤其β-淀粉样蛋白)相关。

研究设计与样本

  • 纵向研究,纳入2,151名基线无痴呆的欧洲血统老年人,基线接受结构化年度临床评估,随访 incident AD和MCI及认知下降。
  • 对死亡者行尸检,记录病理AD并量化β-淀粉样蛋白和神经原纤维缠结。
  • 按APOE基因型分为ε2ε4、ε4(ε4ε4、ε4ε3)、ε2(ε2ε2、ε2ε3)和ε3ε3参考组。
  • 采用Cox比例风险模型分析 incident AD和MCI,线性混合效应模型分析认知下降,逻辑回归和线性回归分析AD病理,均校正年龄、性别和教育。

主要发现

  • 2,151名参与者中,ε2ε4占2.1%,ε3/4和4/4占21.8%,ε2/3和2/2占14.0%,ε3ε3占62.1%。
  • ε2ε4与ε3ε3相比,AD风险无差异。
  • 基线无认知损害者中,ε2ε4携带者较ε3ε3携带者 incident MCI风险升高(HR 2.13,95%CI 1.34-3.39,p=0.002),认知下降更快(估计值-0.047,SE 0.018,p=0.008)。
  • 死亡者(n=1,100)中,ε2ε4较ε3ε3病理AD的比值比增加3倍,β-淀粉样蛋白负荷更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association of the APOE ε2ε4 genotype with incident Alzheimer disease (AD), mild cognitive impairment (MCI), cognitive decline, and AD pathology in older adults. METHODS: We used data from 2,151 older adults of European ancestry who were free of dementia at baseline and underwent structured annual clinical evaluation in a longitudinal study for incident AD and MCI, and cognitive decline. Postmortem examination in decedents documented pathologic AD and quantified β-amyloid and neurofibrillary tangles. Participants were stratified into 4 groups based on APOE genotyping: ε2ε4, ε4 (ε4ε4, ε4ε3), ε2 (ε2ε2, ε2ε3), with ε3ε3 carriers serving as the reference group. We used Cox proportional hazards models to examine the association of APOE genotype with incident AD and MCI. Linear mixed-effect models were used to examine the association with cognitive decline. Logistic and linear regression models were used to examine AD pathology. All the models controlled for age, sex, and education. RESULTS: Of the 2,151 participants included in this study, ε2ε4 accounted for 2.1%, ε3/4 and 4/4 21.8%, ε2/3 and 2/2 14.0%, and ε3ε3 62.1%. We did not observe a difference in the risk of AD for ε2ε4 compared to ε3ε3. In cases without cognitive impairment at baseline, ε2ε4 carriers had an increased risk of incident MCI (hazard ratio 2.13, 95% confidence interval 1.34-3.39, p = 0.002) and a faster rate of cognitive decline (estimate -0.047, SE 0.018, p = 0.008) compared to ε3ε3 carriers. In decedents (n = 1,100), ε2ε4 showed a 3-fold increased odds of pathologic AD and a higher β-amyloid load than ε3ε3. CONCLUSION: APOE ε2ε4 genotype in older adults is associated with risk of MCI, cognitive decline, and a greater burden of AD pathology, especially β-amyloid.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Oveisgharan S, Buchman AS, Yu L, et al. APOE ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults. Neurology. 2018. PMID: 29752306. doi:10.1212/WNL.0000000000005677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。